Mechanisms of Action
Tramadol operates through a dual mechanism combining weak μ-opioid receptor agonism with inhibition of norepinephrine and serotonin reuptake, while diclofenac works by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes to reduce prostaglandin synthesis.
Tramadol Mechanism
Tramadol's analgesic effect derives from two complementary pathways 1:
Opioid Component
- Parent compound: Weak μ-opioid receptor binding with low affinity
- M1 metabolite (O-desmethyltramadol): High-affinity μ-opioid receptor binding
- Up to 6 times more potent than tramadol for analgesia
- 200 times more potent in μ-opioid binding
- Formed via CYP2D6 metabolism
- Tramadol-induced analgesia is only partially antagonized by naloxone, confirming additional non-opioid mechanisms 1
Monoamine Reuptake Inhibition
- Inhibits reuptake of norepinephrine and serotonin in vitro 1
- These mechanisms contribute independently to the overall analgesic profile
- The relative contribution of each pathway depends on plasma concentrations of both tramadol and M1 1
Clinical Implications
According to NCCN guidelines, tramadol should be used with caution or avoided in patients taking other serotonergic medications (tricyclic antidepressants, SSRIs, SNRIs, MAO inhibitors) due to serotonin syndrome risk 2. Additionally, tramadol exhibits marked variability in drug metabolism—CYP2D6 poor metabolizers lack analgesic effect while ultrarapid metabolizers face increased toxicity risk 2.
Diclofenac Mechanism
Diclofenac functions through a well-established anti-inflammatory pathway 3:
COX Inhibition
- Potent inhibitor of both COX-1 and COX-2 enzymes
- Blocks prostaglandin synthesis in peripheral tissues
- Prostaglandins normally:
- Sensitize afferent nerves
- Potentiate bradykinin-induced pain
- Mediate inflammatory responses
Analgesic Effect
The decrease in peripheral prostaglandins produces:
- Analgesic properties (pain relief)
- Anti-inflammatory effects (reduced inflammation)
- Antipyretic activity (fever reduction)
Diclofenac achieves these effects through direct enzyme inhibition rather than receptor-mediated mechanisms, making it fundamentally different from tramadol's centrally-acting approach 3.
Combined Use Rationale
The tramadol/diclofenac fixed-dose combination leverages non-redundant mechanisms to provide multimodal analgesia 4. This approach allows:
- Lower doses of each individual agent
- Reduced side effects compared to higher doses of single agents
- Complementary pain relief through both central (tramadol) and peripheral (diclofenac) pathways
Important caveat: While tramadol is considered approximately one-tenth as potent as morphine, evidence suggests it may be less effective than morphine for cancer pain, with potentially more adverse effects including vomiting, dizziness, and weakness 5, 2.